Salbutamol dry-powder inhalation - sanofi-aventis

Drug Profile

Salbutamol dry-powder inhalation - sanofi-aventis

Alternative Names: Albuterol dry-powder inhalation - sanofi-aventis; Albuterol Ultrahaler; Salbutamol Ultrahaler

Latest Information Update: 26 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 26 Mar 2009 No development reported - Phase-III for Asthma in Europe (Inhalation)
  • 26 Mar 2009 No development reported - Phase-III for Asthma in USA (Inhalation)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top